Assistant professor in Genetics and Biochemistry Dr. Stephen Dolan, who is also a part of the Eukaryotic Pathogens Innovation Center (EPIC), has joined forces with molecular biologist Gustavo Goldman at the University of São Paulo in Brazil to understand how dangerous fungi survive their own poisons and how that could be turned into a new antifungal drug.
The two researchers work on the fungi Aspergillus fumigatus, a common mold that can cause life-threatening lung infections in people with weakened immune systems. A. fumigatus produces a potent toxin called gliotoxin that enables the fungus to cause disease and outcompete other microbes, but it is also so toxic that it can poison the fungus itself. To survive, the fungus has developed protective systems that neutralize gliotoxin.
With Dolan specializing in creating mutant strains of fungi and analyzing the resulting data to see which genes matter most for survival and Goldman’s strengths in fungal genetics and biochemistry, the team was able to connect molecular mechanisms to big-picture questions about how fungi cause disease.
Together they discovered that mitochondria are a key weak spot for gliotoxin. The toxin disrupts mitochondrial function, and when defenses fail, the fungus’s energy systems collapse, leading to cell death. The results reveal new details about how fungi defend themselves against their own toxins and highlight mitochondria as a possible target for future antifungal treatments, which is important because drug resistance is on the rise and current treatments for fungal infections can be toxic or ineffective.
Dolan has actually been working with Goldman since his Ph.D. and they have published two papers together, with more forthcoming and they’ve started participating in virtual joint lab meetings once a month. Dolan believes that collaboration in research is essential for impactful work.
“The mindset of working independently without engaging other labs is disappearing,” Dolan says.
Read more in the Clemson News article.
